Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. / Persson, Morten; El Ali, Henrik H; Binderup, Tina; Pfeifer, Andreas; Madsen, Jacob; Rasmussen, Palle; Kjaer, Andreas.

In: Nuclear Medicine and Biology, Vol. 41, No. 3, 03.2014, p. 290-5.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Persson, M, El Ali, HH, Binderup, T, Pfeifer, A, Madsen, J, Rasmussen, P & Kjaer, A 2014, 'Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging', Nuclear Medicine and Biology, vol. 41, no. 3, pp. 290-5. https://doi.org/10.1016/j.nucmedbio.2013.12.007

APA

Persson, M., El Ali, H. H., Binderup, T., Pfeifer, A., Madsen, J., Rasmussen, P., & Kjaer, A. (2014). Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. Nuclear Medicine and Biology, 41(3), 290-5. https://doi.org/10.1016/j.nucmedbio.2013.12.007

Vancouver

Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P et al. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. Nuclear Medicine and Biology. 2014 Mar;41(3):290-5. https://doi.org/10.1016/j.nucmedbio.2013.12.007

Author

Persson, Morten ; El Ali, Henrik H ; Binderup, Tina ; Pfeifer, Andreas ; Madsen, Jacob ; Rasmussen, Palle ; Kjaer, Andreas. / Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. In: Nuclear Medicine and Biology. 2014 ; Vol. 41, No. 3. pp. 290-5.

Bibtex

@article{418a92c08fb4426b9d9266ef4b4758cb,
title = "Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging",
abstract = "UNLABELLED: (64)Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human urokinase-type plasminogen activator receptor (uPAR). In preparation of using this tracer in humans, as a new promising method to distinguish between indolent and aggressive cancers, we have performed PET studies in mice to evaluate the in vivo biodistribution and estimate human dosimetry of (64)Cu-DOTA-AE105.METHODS: Five mice received iv tail injection of (64)Cu-DOTA-AE105 and were PET/CT scanned 1, 4.5 and 22 h post injection. Volume-of-interest (VOI) were manually drawn on the following organs: heart, lung, liver, kidney, spleen, intestine, muscle, bone and bladder. The activity concentrations in the mentioned organs [{\%}ID/g] were used for the dosimetry calculation. The {\%}ID/g of each organ at 1, 4.5 and 22 h was scaled to human value based on a difference between organ and body weights. The scaled values were then exported to OLINDA software for computation of the human absorbed doses. The residence times as well as effective dose equivalent for male and female could be obtained for each organ. To validate this approach, of human projection using mouse data, five mice received iv tail injection of another (64)Cu-DOTA peptide-based tracer, (64)Cu-DOTA-TATE, and underwent same procedure as just described. The human dosimetry estimates were then compared with observed human dosimetry estimate recently found in a first-in-man study using (64)Cu-DOTA-TATE.RESULTS: Human estimates of (64)Cu-DOTA-AE105 revealed the heart wall to receive the highest dose (0.0918 mSv/MBq) followed by the liver (0.0815 mSv/MBq), All other organs/tissue were estimated to receive doses in the range of 0.02-0.04 mSv/MBq. The mean effective whole-body dose of (64)Cu-DOTA-AE105 was estimated to be 0.0317 mSv/MBq. Relatively good correlation between human predicted and observed dosimetry estimates for (64)Cu-DOTA-TATE was found. Importantly, the effective whole body dose was predicted with very high precision (predicted value: 0.0252 mSv/Mbq, Observed value: 0.0315 mSv/MBq) thus validating our approach for human dosimetry estimation.CONCLUSION: Favorable dosimetry estimates together with previously reported uPAR PET data fully support human testing of (64)Cu-DOTA-AE105.",
keywords = "Animals, Copper Radioisotopes, Female, Humans, Male, Mice, Peptides, Positron-Emission Tomography, Radioactive Tracers, Radiometry, Receptors, Urokinase Plasminogen Activator",
author = "Morten Persson and {El Ali}, {Henrik H} and Tina Binderup and Andreas Pfeifer and Jacob Madsen and Palle Rasmussen and Andreas Kjaer",
note = "Copyright {\circledC} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = "3",
doi = "10.1016/j.nucmedbio.2013.12.007",
language = "English",
volume = "41",
pages = "290--5",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging

AU - Persson, Morten

AU - El Ali, Henrik H

AU - Binderup, Tina

AU - Pfeifer, Andreas

AU - Madsen, Jacob

AU - Rasmussen, Palle

AU - Kjaer, Andreas

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/3

Y1 - 2014/3

N2 - UNLABELLED: (64)Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human urokinase-type plasminogen activator receptor (uPAR). In preparation of using this tracer in humans, as a new promising method to distinguish between indolent and aggressive cancers, we have performed PET studies in mice to evaluate the in vivo biodistribution and estimate human dosimetry of (64)Cu-DOTA-AE105.METHODS: Five mice received iv tail injection of (64)Cu-DOTA-AE105 and were PET/CT scanned 1, 4.5 and 22 h post injection. Volume-of-interest (VOI) were manually drawn on the following organs: heart, lung, liver, kidney, spleen, intestine, muscle, bone and bladder. The activity concentrations in the mentioned organs [%ID/g] were used for the dosimetry calculation. The %ID/g of each organ at 1, 4.5 and 22 h was scaled to human value based on a difference between organ and body weights. The scaled values were then exported to OLINDA software for computation of the human absorbed doses. The residence times as well as effective dose equivalent for male and female could be obtained for each organ. To validate this approach, of human projection using mouse data, five mice received iv tail injection of another (64)Cu-DOTA peptide-based tracer, (64)Cu-DOTA-TATE, and underwent same procedure as just described. The human dosimetry estimates were then compared with observed human dosimetry estimate recently found in a first-in-man study using (64)Cu-DOTA-TATE.RESULTS: Human estimates of (64)Cu-DOTA-AE105 revealed the heart wall to receive the highest dose (0.0918 mSv/MBq) followed by the liver (0.0815 mSv/MBq), All other organs/tissue were estimated to receive doses in the range of 0.02-0.04 mSv/MBq. The mean effective whole-body dose of (64)Cu-DOTA-AE105 was estimated to be 0.0317 mSv/MBq. Relatively good correlation between human predicted and observed dosimetry estimates for (64)Cu-DOTA-TATE was found. Importantly, the effective whole body dose was predicted with very high precision (predicted value: 0.0252 mSv/Mbq, Observed value: 0.0315 mSv/MBq) thus validating our approach for human dosimetry estimation.CONCLUSION: Favorable dosimetry estimates together with previously reported uPAR PET data fully support human testing of (64)Cu-DOTA-AE105.

AB - UNLABELLED: (64)Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human urokinase-type plasminogen activator receptor (uPAR). In preparation of using this tracer in humans, as a new promising method to distinguish between indolent and aggressive cancers, we have performed PET studies in mice to evaluate the in vivo biodistribution and estimate human dosimetry of (64)Cu-DOTA-AE105.METHODS: Five mice received iv tail injection of (64)Cu-DOTA-AE105 and were PET/CT scanned 1, 4.5 and 22 h post injection. Volume-of-interest (VOI) were manually drawn on the following organs: heart, lung, liver, kidney, spleen, intestine, muscle, bone and bladder. The activity concentrations in the mentioned organs [%ID/g] were used for the dosimetry calculation. The %ID/g of each organ at 1, 4.5 and 22 h was scaled to human value based on a difference between organ and body weights. The scaled values were then exported to OLINDA software for computation of the human absorbed doses. The residence times as well as effective dose equivalent for male and female could be obtained for each organ. To validate this approach, of human projection using mouse data, five mice received iv tail injection of another (64)Cu-DOTA peptide-based tracer, (64)Cu-DOTA-TATE, and underwent same procedure as just described. The human dosimetry estimates were then compared with observed human dosimetry estimate recently found in a first-in-man study using (64)Cu-DOTA-TATE.RESULTS: Human estimates of (64)Cu-DOTA-AE105 revealed the heart wall to receive the highest dose (0.0918 mSv/MBq) followed by the liver (0.0815 mSv/MBq), All other organs/tissue were estimated to receive doses in the range of 0.02-0.04 mSv/MBq. The mean effective whole-body dose of (64)Cu-DOTA-AE105 was estimated to be 0.0317 mSv/MBq. Relatively good correlation between human predicted and observed dosimetry estimates for (64)Cu-DOTA-TATE was found. Importantly, the effective whole body dose was predicted with very high precision (predicted value: 0.0252 mSv/Mbq, Observed value: 0.0315 mSv/MBq) thus validating our approach for human dosimetry estimation.CONCLUSION: Favorable dosimetry estimates together with previously reported uPAR PET data fully support human testing of (64)Cu-DOTA-AE105.

KW - Animals

KW - Copper Radioisotopes

KW - Female

KW - Humans

KW - Male

KW - Mice

KW - Peptides

KW - Positron-Emission Tomography

KW - Radioactive Tracers

KW - Radiometry

KW - Receptors, Urokinase Plasminogen Activator

U2 - 10.1016/j.nucmedbio.2013.12.007

DO - 10.1016/j.nucmedbio.2013.12.007

M3 - Journal article

C2 - 24533988

VL - 41

SP - 290

EP - 295

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 3

ER -

ID: 139856315